{
    "id": 24286,
    "fullName": "FGFR4 V550M",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FGFR4 V550M lies within the protein kinase domain of the Fgfr4 protein (UniProt.org). V550M has been demonstrated to confer resistance to Fgfr4 inhibitors as a secondary resistance mutation (PMID: 31575540), but has not been biochemically characterized and therefore, its effect on Fgfr4 protein function is unknown (PubMed, Dec 2019).",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2264,
        "geneSymbol": "FGFR4",
        "terms": [
            "FGFR4",
            "CD334",
            "JTK2",
            "TKF"
        ]
    },
    "variant": "V550M",
    "createDate": "07/13/2016",
    "updateDate": "12/19/2019",
    "referenceTranscriptCoordinates": {
        "id": 164682,
        "transcript": "NM_213647",
        "gDna": "chr5:g.177095550G>A",
        "cDna": "c.1648G>A",
        "protein": "p.V550M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19588,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with hepatocellular carcinoma overexpressing FGF19 initially responded to Fisogatinib (BLU-554) treatment, but progressed at week 32 and was found via circulating tumor DNA testing to have acquired FGFR4 V550M, FGFR4 V550L, and FGFR4 C552R (PMID: 31575540).",
            "molecularProfile": {
                "id": 34258,
                "profileName": "FGF19 over exp FGFR4 V550L FGFR4 V550M FGFR4 C552R"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19589,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with hepatocellular carcinoma and overexpression of FGF19 initially experienced stable disease and a 15% decrease in tumor size when treated with Fisogatinib (BLU-554), but then progressed and was found via circulating tumor DNA to have acquired FGFR4 V550M (PMID: 31575540).",
            "molecularProfile": {
                "id": 34266,
                "profileName": "FGF19 over exp FGFR4 V550M"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19609,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line xenograft model with FGF19 amplification, FGFR4 and KLB expression, and FGFR4 V550M demonstrated delayed tumor growth when treated with LY2874455 (PMID: 31575540).",
            "molecularProfile": {
                "id": 34277,
                "profileName": "FGF19 amp FGFR4 V550M FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19601,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line xenograft model with FGF19 amplification and FGFR4 and KLB expression demonstrated resistance to treatment with Fisogatinib (BLU-554) and was subsequently found to have acquired FGFR4 V550M (PMID: 31575540).",
            "molecularProfile": {
                "id": 34277,
                "profileName": "FGF19 amp FGFR4 V550M FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19605,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2874455 treatment inhibited proliferation of cells co-expressing ETV6-FGFR4 and FGFR4 V550M in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34279,
                "profileName": "ETV6 - FGFR4 FGFR4 V550M"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25018,
            "profileName": "FGFR4 V550M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34258,
            "profileName": "FGF19 over exp FGFR4 V550L FGFR4 V550M FGFR4 C552R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34266,
            "profileName": "FGF19 over exp FGFR4 V550M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34277,
            "profileName": "FGF19 amp FGFR4 V550M FGFR4 pos KLB pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34279,
            "profileName": "ETV6 - FGFR4 FGFR4 V550M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 164685,
            "transcript": "XM_005265838",
            "gDna": "chr5:g.177095550G>A",
            "cDna": "c.1648G>A",
            "protein": "p.V550M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 164683,
            "transcript": "NM_002011",
            "gDna": "chr5:g.177095550G>A",
            "cDna": "c.1648G>A",
            "protein": "p.V550M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 164686,
            "transcript": "NM_022963",
            "gDna": "chr5:g.177095670_177095672delGTCinsATG",
            "cDna": "c.1648_1650delGTCinsATG",
            "protein": "p.V550M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 164684,
            "transcript": "NM_001291980",
            "gDna": "chr5:g.177096087G>A",
            "cDna": "c.1648G>A",
            "protein": "p.V550M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 164682,
            "transcript": "NM_213647",
            "gDna": "chr5:g.177095550G>A",
            "cDna": "c.1648G>A",
            "protein": "p.V550M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}